|
May 2
|
Galapagos reports first quarter 2024 financial results
|
|
Apr 30
|
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
|
|
Apr 24
|
Down -9.97% in 4 Weeks, Here's Why You Should You Buy the Dip in Galapagos (GLPG)
|
|
Apr 4
|
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
|
|
Apr 3
|
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
|
|
Mar 28
|
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
|
|
Mar 26
|
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
|
|
Mar 18
|
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
|
|
Mar 17
|
11 Oversold Biotech Stocks To Buy Right Now
|
|
Jan 2
|
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
|
|
Dec 19
|
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
|
|
Dec 9
|
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
|
|
Dec 7
|
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
|